WEBULL
News
BMYMP
1002.93
NaN%
--
This Is A Stock Picker's Market
Seeking Alpha · 1d ago
Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength
Seeking Alpha · 2d ago
Weekly Report: what happened at BMYMP last week (0209-0213)?
Weekly Report · 5d ago
Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff
Seeking Alpha · 02/11 15:00
Weekly Report: what happened at BMYMP last week (0202-0206)?
Weekly Report · 02/09 09:41
Bristol-Myers Squibb outlines $46B–$47.5B 2026 revenue target as growth portfolio nears 60% of sales, driven by new product launches and pipeline catalysts
Seeking Alpha · 02/05 23:05
Weekly Report: what happened at BMYMP last week (0126-0130)?
Weekly Report · 02/02 09:40
Weekly Report: what happened at BMYMP last week (0119-0123)?
Weekly Report · 01/26 09:40
Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion
Seeking Alpha · 01/23 20:52
Weekly Report: what happened at BMYMP last week (0112-0116)?
Weekly Report · 01/19 09:44
XLV Vs. BME: Total Return Or Income, Which Healthcare Strategy Wins?
Seeking Alpha · 01/14 17:39
Weekly Report: what happened at BMYMP last week (0105-0109)?
Weekly Report · 01/12 09:42
Weekly Report: what happened at BMYMP last week (1229-0102)?
Weekly Report · 01/05 09:40
Weekly Report: what happened at BMYMP last week (1222-1226)?
Weekly Report · 12/29/2025 09:39
SCHD: Coming Redemption Year; 2026 Could Favor Dividend Discipline
Seeking Alpha · 12/28/2025 15:00
Teva Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)
Seeking Alpha · 12/23/2025 23:08
Bristol-Myers Squibb: Pharma Giant Still Undervalued And Printing Cash Despite Patent Cliff
Seeking Alpha · 12/23/2025 16:30
Weekly Report: what happened at BMYMP last week (1215-1219)?
Weekly Report · 12/22/2025 09:39
SCHD: This ETF Stinks
Seeking Alpha · 12/17/2025 23:50
Weekly Report: what happened at BMYMP last week (1208-1212)?
Weekly Report · 12/15/2025 09:43
More
Webull provides a variety of real-time BMYMP stock news. You can receive the latest news about Bristol Myers through multiple platforms. This information may help you make smarter investment decisions.
About BMYMP
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.